Sandeep Randhawa, MD
Retina Specialist · Royal Oak, MINPI 1841486172
Payments from drug & device makers
Across 219 payments — averaging $446.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$84K
- Alimera Sciences, Inc.$5K
- Janssen Research & Development, LLC$4K
- Astellas Pharma US Inc$3K
- Genentech USA, Inc.$528
- AbbVie$435
- plus $2K from 13 others
What the payments were for
- Consulting fees$5,4206%
- Speaking & faculty fees$77,37682%
- Travel & lodging$5011%
- Food & beverage$10,94312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 102 | $83,694 |
| Alimera Sciences, Inc. | 22 | $5,149 |
| Janssen Research & Development, LLC | 3 | $3,605 |
| Astellas Pharma US Inc | 11 | $2,850 |
| Genentech USA, Inc. | 24 | $528 |
| AbbVie(2 entities) | 21 | $435 |
| Regeneron | 2 | $250 |
| Novartis | 8 | $220 |
| Abiomed | 2 | $217 |
| ANI Pharmaceuticals, Inc. | 4 | $194 |
| Mallinckrodt Enterprises LLC | 5 | $188 |
| Bausch & Lomb Americas Inc. | 3 | $160 |
| Biogen | 6 | $148 |
| Genentech, Inc. | 1 | $73 |
| Alcon | 1 | $55 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Eyepoint US, Inc. | 1 | $16 |
| Harrow Eye, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,845 in reported general payments places this provider in the 70th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 73 | $3,782 |
| Latanoprost | 101 | $1,809 |
| Brimonidine Tartrate | 56 | $1,701 |
| Difluprednate | 13 | $1,423 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $641 |
| Atropine Sulfate | 14 | $441 |
| ErythromycinErythromycin Base | 23 | $403 |
| Ketorolac Tromethamine | 11 | $295 |
| Ofloxacin | 19 | $225 |
| Acetazolamide ErAcetazolamide | 13 | $172 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Royal Oak
- Jeremy WolfeRoyal Oak$3.6M
- Tarek HassanRoyal Oak$801K
- Lisa FaiaRoyal Oak$657K
- Antonio CaponeRoyal Oak$179K
- Kimberly DrenserRoyal Oak$87K
- Michael TreseRoyal Oak$69K
- Adam WeinerRoyal Oak$31K
- Ramon LeeRoyal Oak$19K
- Jong ParkRoyal Oak$12K
- Tianyu LiuRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.